Cargando...
Payers Move Slowly on Test Coverage Decisions
Formulary decisions might be considered a snap when compared to decisions about coverage of a genetic test. The presence – or lack – of credible data to demonstrate cost-effectiveness is usually the touchstone.
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioCommunications LLC
2005
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3564335/ https://ncbi.nlm.nih.gov/pubmed/23393473 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|